Re: Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial

Re: Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European urology 2022-11, Vol.82 (5), p.572-572
Hauptverfasser: Kesch, Claudia, Hadaschik, Boris A.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 572
container_issue 5
container_start_page 572
container_title European urology
container_volume 82
creator Kesch, Claudia
Hadaschik, Boris A.
description
doi_str_mv 10.1016/j.eururo.2022.07.030
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2702180397</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0302283822025465</els_id><sourcerecordid>2702180397</sourcerecordid><originalsourceid>FETCH-LOGICAL-c288t-e887abe56c217383f9b3ca0c3db431a31494e72b0b924f5eddb8bcd5b5d1f0643</originalsourceid><addsrcrecordid>eNp9kc1u2zAQhIWgBeKmfYMeeOxFKn8ki8qhgCE4bQC3MVL3TFDkCqZLiS5JOUiero8WOuqxyGmBwXwDzE6WfSS4IJgsPx8KmPzkXUExpQWuC8zwRbYgvGZ5XS3xm2yRFJpTzvhl9i6EA8aYVQ1bZH_v4RqtVDQnQD8nfwJjrRwVoK2dAlqPT9JOUQ5GA_ruRhf34OXxEZ3Cf6GVdSMgM6KtjAbGGNCDiXu0cQ-5N-E3ch7djhH8ANrICLO4cUpa8wQabb0LMemoPaf5a7TbA1r_WLU7dC9H7YYXV2vNaBKCdt5I-z5720sb4MO_e5X9ulnv2m_55u7rbbva5IpyHnPgvJYdVEtFSc0465uOKYkV013JiGSkbEqoaYe7hpZ9BVp3vFO66ipNerws2VX2ac49evdnghDFYIKCc3FwUxC0xpRwzJo6WcvZqlKf4KEXR28G6R8FweI8mDiIeTBxHkzgWqR5EvZlxiDVOBnwIqj0RJV-5UFFoZ15PeAZ_CilGg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2702180397</pqid></control><display><type>article</type><title>Re: Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Kesch, Claudia ; Hadaschik, Boris A.</creator><creatorcontrib>Kesch, Claudia ; Hadaschik, Boris A.</creatorcontrib><identifier>ISSN: 0302-2838</identifier><identifier>EISSN: 1873-7560</identifier><identifier>DOI: 10.1016/j.eururo.2022.07.030</identifier><language>eng</language><publisher>Elsevier B.V</publisher><ispartof>European urology, 2022-11, Vol.82 (5), p.572-572</ispartof><rights>2022 European Association of Urology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c288t-e887abe56c217383f9b3ca0c3db431a31494e72b0b924f5eddb8bcd5b5d1f0643</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.eururo.2022.07.030$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids></links><search><creatorcontrib>Kesch, Claudia</creatorcontrib><creatorcontrib>Hadaschik, Boris A.</creatorcontrib><title>Re: Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial</title><title>European urology</title><issn>0302-2838</issn><issn>1873-7560</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u2zAQhIWgBeKmfYMeeOxFKn8ki8qhgCE4bQC3MVL3TFDkCqZLiS5JOUiero8WOuqxyGmBwXwDzE6WfSS4IJgsPx8KmPzkXUExpQWuC8zwRbYgvGZ5XS3xm2yRFJpTzvhl9i6EA8aYVQ1bZH_v4RqtVDQnQD8nfwJjrRwVoK2dAlqPT9JOUQ5GA_ruRhf34OXxEZ3Cf6GVdSMgM6KtjAbGGNCDiXu0cQ-5N-E3ch7djhH8ANrICLO4cUpa8wQabb0LMemoPaf5a7TbA1r_WLU7dC9H7YYXV2vNaBKCdt5I-z5720sb4MO_e5X9ulnv2m_55u7rbbva5IpyHnPgvJYdVEtFSc0465uOKYkV013JiGSkbEqoaYe7hpZ9BVp3vFO66ipNerws2VX2ac49evdnghDFYIKCc3FwUxC0xpRwzJo6WcvZqlKf4KEXR28G6R8FweI8mDiIeTBxHkzgWqR5EvZlxiDVOBnwIqj0RJV-5UFFoZ15PeAZ_CilGg</recordid><startdate>202211</startdate><enddate>202211</enddate><creator>Kesch, Claudia</creator><creator>Hadaschik, Boris A.</creator><general>Elsevier B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202211</creationdate><title>Re: Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial</title><author>Kesch, Claudia ; Hadaschik, Boris A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c288t-e887abe56c217383f9b3ca0c3db431a31494e72b0b924f5eddb8bcd5b5d1f0643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kesch, Claudia</creatorcontrib><creatorcontrib>Hadaschik, Boris A.</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kesch, Claudia</au><au>Hadaschik, Boris A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Re: Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial</atitle><jtitle>European urology</jtitle><date>2022-11</date><risdate>2022</risdate><volume>82</volume><issue>5</issue><spage>572</spage><epage>572</epage><pages>572-572</pages><issn>0302-2838</issn><eissn>1873-7560</eissn><pub>Elsevier B.V</pub><doi>10.1016/j.eururo.2022.07.030</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0302-2838
ispartof European urology, 2022-11, Vol.82 (5), p.572-572
issn 0302-2838
1873-7560
language eng
recordid cdi_proquest_miscellaneous_2702180397
source Elsevier ScienceDirect Journals Complete
title Re: Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T22%3A23%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Re:%20Active%20Surveillance%20Plus%20Enzalutamide%20Monotherapy%20vs%20Active%20Surveillance%20Alone%20in%20Patients%20with%20Low-risk%20or%20Intermediate-risk%20Localized%20Prostate%20Cancer:%20The%20ENACT%20Randomized%20Clinical%20Trial&rft.jtitle=European%20urology&rft.au=Kesch,%20Claudia&rft.date=2022-11&rft.volume=82&rft.issue=5&rft.spage=572&rft.epage=572&rft.pages=572-572&rft.issn=0302-2838&rft.eissn=1873-7560&rft_id=info:doi/10.1016/j.eururo.2022.07.030&rft_dat=%3Cproquest_cross%3E2702180397%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2702180397&rft_id=info:pmid/&rft_els_id=S0302283822025465&rfr_iscdi=true